Slideshow: FierceBiotech's 2012 Fierce 15 at BioPharm America

Click here to view the slideshow >>

Months of work culminated in the announcement of FierceBiotech's 2012 Fierce 15 on Wednesday in Boston at the BioPharm America conference. Every year the Fierce 15 seems to become a bigger deal for us, so it was gratifying to see all the hard work of the companies and our staff pay off during an awards ceremony. This year's crop of Fierce 15 companies shows that you've got to be working on something potentially transformational for patients in order to attract support from investors and partners.

Nick Leschly, the CEO of Bluebird Bio, playfully dubbed the ambitious spirit of biotechs Levin Syndrome, a fictional affliction named after Third Rock Ventures' Mark Levin that compels biotech entrepreneurs to, as they say, go big or go home. Our Fierce 15 companies are all "going big." They also went home… with trophies. Click here to check out the slideshow. -- Ryan McBride (email | Twitter)

Here's the full FierceBiotech 2012 Fierce 15 report >>

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.